Ozempic vs Jardiance for Weight Loss: How They Compare

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) and Jardiance (empagliflozin) are two medications frequently discussed for weight management, yet they operate through entirely different biological mechanisms. While Ozempic belongs to the GLP-1 receptor agonist class, Jardiance is an SGLT2 inhibitor originally developed for blood sugar control. Knowing how each medication affects your body can guide you toward the right treatment choice.

How Ozempic and Jardiance Work Differently in Your Body

Ozempic activates GLP-1 receptors in your brain and digestive system, triggering signals that reduce hunger, slow stomach emptying, and increase feelings of fullness after eating. This central appetite suppression mechanism produces the primary weight loss benefit most patients experience. Studies show Ozempic users typically see 15-22% body weight reduction over 68 weeks when combined with lifestyle changes.

Jardiance functions as an SGLT2 inhibitor, which means it blocks glucose reabsorption in your kidneys, allowing excess glucose to be eliminated through urine. This process naturally reduces blood sugar levels but produces modest weight loss—typically 2-3 kg over 12 weeks—primarily through water loss and modest calorie reduction. Jardiance was designed first as a diabetes medication and carries secondary weight management benefits rather than primary appetite suppression.

Weight Loss Results: Comparing Clinical Trial Data

Head-to-head clinical evidence strongly favors GLP-1 medications like Ozempic for weight loss outcomes. In the SUSTAIN trials, semaglutide-treated patients achieved mean weight reductions of 10-15% of baseline body weight, with some reaching 20%+ loss at higher doses. Jardiance trials showed average weight loss of 2-3 kg, making it substantially less effective for patients whose primary goal is significant weight reduction.

The magnitude of difference reflects each drug's biological action. Since Ozempic directly suppresses appetite through brain-based mechanisms, users typically consume fewer calories voluntarily and maintain that reduction long-term. Jardiance's weight loss remains limited because the SGLT2 pathway does not address hunger signals, relying instead on indirect calorie loss through glucosuria (glucose in urine) and metabolic adjustments.

Side Effects and Tolerability Profiles

Ozempic commonly produces gastrointestinal side effects during the first 4-8 weeks, including nausea, vomiting, diarrhea, and constipation. These effects typically diminish as your body adapts, and starting at low doses minimizes severity. Serious but rare complications include pancreatitis and gallbladder issues; patients with personal or family history of medullary thyroid cancer should avoid GLP-1 medications.

Jardiance presents a different side effect profile centered on urinary and genital tract infections, occurring in roughly 10% of users due to elevated glucose in urine creating an environment where bacteria thrive. Dehydration-related complications are possible, particularly in elderly patients or those taking diuretics. Both medications are generally safe when prescribed appropriately, but Ozempic's side effects tend to improve with continued use while Jardiance's infection risk persists.

Which Medication May Be Right for Your Weight Loss Goals

Choose Ozempic if your primary objective is substantial weight loss (15%+ of body weight), you want appetite-based appetite suppression, and you can tolerate initial gastrointestinal adaptation. Ozempic delivery through compounded semaglutide injection provides flexibility without insurance requirements—PlexusDx offers compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiers, with the pricing principle that your dose may increase but your monthly cost remains flat.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cost, Access, and Treatment Duration Considerations

Ozempic (brand name) typically costs $900-1,200 per month through traditional pharmacies with insurance or cash pay. PlexusDx compounded semaglutide injection achieves equivalent therapeutic effects at $189/mo starting rate—no insurance required, HSA/FSA eligible, and available across all 50 states. The compounded formulation is manufactured in licensed 503A compounding pharmacies meeting pharmaceutical-grade standards, offering significant cost savings without compromising quality.

Jardiance costs $400-600 monthly through standard channels, positioning it between compounded semaglutide and brand Ozempic in price. Treatment duration differs importantly: Ozempic requires ongoing use to maintain weight loss (weight typically returns within months of stopping), while Jardiance continues indefinitely if blood sugar management is the primary indication. PlexusDx medications serve patients seeking long-term GLP-1 therapy as a sustainable approach to weight management alongside lifestyle modifications.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic actually better for weight loss than Jardiance?

Yes, clinical evidence shows Ozempic (semaglutide) produces 15-22% body weight reduction versus Jardiance's 2-3% average loss. Ozempic's GLP-1 mechanism directly suppresses appetite through brain signals, while Jardiance works through a different pathway (SGLT2 inhibition) with weight loss as a secondary effect. For patients whose primary goal is significant weight loss, Ozempic-class medications consistently outperform SGLT2 inhibitors.

Can I take Ozempic and Jardiance together for better results?

Combining medications should only be done under direct physician supervision, as both affect glucose metabolism and hydration status. Some doctors explore dual-therapy approaches in complex cases, but starting monotherapy with the most effective single agent is standard practice. PlexusDx offers GLP-Squared (dual semaglutide and tirzepatide compound), which combines two GLP-1 mechanisms—a different dual approach than mixing GLP-1 with SGLT2 inhibitors.

Why does PlexusDx compounded semaglutide cost so much less than brand Ozempic?

Brand Ozempic includes manufacturing, marketing, and distribution costs for a branded pharmaceutical product. PlexusDx compounded semaglutide is manufactured in licensed 503A compounding pharmacies, eliminating middleman markups and brand premium expenses. The active pharmaceutical compound is identical, meeting the same purity standards, allowing PlexusDx to offer treatment at $189/mo month-to-month, or from $149/mo on the 6-month plan—with the principle that your dose may increase but your monthly price remains flat.

What side effects should I expect with Ozempic compared to Jardiance?

Ozempic commonly causes nausea, vomiting, and digestive changes in the first 4-8 weeks that typically improve with continued use. Jardiance's side effects center on urinary tract and genital infections due to elevated urine glucose. Both are manageable, but Ozempic's GI effects are usually temporary while Jardiance's infection risk persists. Your personal medical history should guide which side effect profile you can better tolerate.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.